Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome

INTRODUCTION: Allogeneic hematopoietic cell transplantation (HCT) was a standard therapy in chronic phase (CP) chronic myeloid leukemia (CML). As a result of the effective therapy with tyrosine kinase inhibitors (TKI), HCT was shifted to defined clinical situations. We present the results of observa...

Descripción completa

Detalles Bibliográficos
Autores principales: Piekarska, Agnieszka, Gil, Lidia, Prejzner, Witold, Wiśniewski, Piotr, Leszczyńska, Aleksandra, Gniot, Michał, Komarnicki, Mieczysław, Hellmann, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569656/
https://www.ncbi.nlm.nih.gov/pubmed/26220759
http://dx.doi.org/10.1007/s00277-015-2457-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569656/
https://www.ncbi.nlm.nih.gov/pubmed/26220759
http://dx.doi.org/10.1007/s00277-015-2457-1

Ejemplares similares